Ikarovec Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Private

  • Employees
  • 8

Employees

  • Latest Deal Type
  • Later Stage VC
  • (In Progress)

  • Latest Deal Amount
  • $46M

  • Investors
  • 7

Ikarovec General Information

Description

Operator of a gene therapy company intended to treat common eye diseases. The company targets multiple disease targets and pathways that help in targeting multiple disease targets and pathways treatment for diabetic macular edema, dry-form age-related macular degeneration, neovascular (wet-form) age-related macular degeneration, and ocular hypertension, enabling patients to get the required treatment for restoring sight and preventing blindness.

Contact Information

Website
www.ikarovec.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Innovation Centre
  • Norwich Research Park, Colney Lane
  • Norwich NR4 7GJ
  • England, United Kingdom
+44 01603
Primary Industry
Drug Discovery
Other Industries
Other Healthcare Services
Vertical(s)
HealthTech, Life Sciences
Corporate Office
  • Innovation Centre
  • Norwich Research Park, Colney Lane
  • Norwich NR4 7GJ
  • England, United Kingdom
+44 01603

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Ikarovec Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Later Stage VC 22-Oct-2025 $46M In Progress Clinical Trials - Phase 1
7. Seed Round 23-Oct-2024 Completed Pre-Clinical Trials
6. Seed Round Completed Pre-Clinical Trials
5. Grant 15-Jun-2020 Completed Pre-Clinical Trials
4. Seed Round 01-Jun-2020 Completed Pre-Clinical Trials
3. Seed Round 09-Aug-2018 Completed Startup
2. Accelerator/Incubator Completed Startup
1. University Spin-Out 07-Aug-2018 Completed Startup
To view Ikarovec’s complete valuation and funding history, request access »

Ikarovec Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
B Ordinary
Ordinary
Ordinary 11,433 $0.013177 $1.32 $1.32 1x $1.32 5.28%
To view Ikarovec’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Ikarovec Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a gene therapy company intended to treat common eye diseases. The company targets multiple disease targets a
Drug Discovery
Norwich, United Kingdom
8 As of 2025

Redwood City, CA
 

London, United Kingdom
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Ikarovec Competitors (6)

One of Ikarovec’s 6 competitors is Adverum Biotechnologies, a Formerly VC-backed company based in Redwood City, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Adverum Biotechnologies Formerly VC-backed Redwood City, CA
Complement Therapeutics Venture Capital-Backed London, United Kingdom
4D Molecular Therapeutics Formerly VC-backed Emeryville, CA
Kriya Therapeutics Venture Capital-Backed Morrisville, NC
AbbVie Corporation North Chicago, IL
To view Ikarovec’s complete competitors history, request access »

Ikarovec Patents

  • 20

    Total Documents Applications and Grants

  • Total Patents Families

  • Granted

  • 10

    Pending

  • Expiring in next 12 mo

Ikarovec Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-202204230-D0 Retinal disorders Inactive 25-Mar-2022
GB-202204231-D0 Retinal disorders Inactive 25-Mar-2022
GB-202204234-D0 Retinal disorders Inactive 25-Mar-2022
GB-202108761-D0 Ocular disorders Inactive 18-Jun-2021
WO-2022263845-A1 Ocular disorders Inactive 18-Jun-2021 C12N15/86
To view Ikarovec’s complete patent history, request access »

Ikarovec Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Ikarovec Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds
Cambridge Enterprise Ventures Venture Capital Minority
Future Planet Capital Venture Capital Minority
LifeArc Ventures Venture Capital Minority
Parkwalk Advisors Venture Capital Minority
UK Innovation & Science Seed Fund Venture Capital Minority
You’re viewing 5 of 7 investors. Get the full list »

Ready to get started?

Request a free trial

Ikarovec FAQs

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process